Department of Neurosurgery, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Department of Neurology, Nippon Medical School Hospital, Tokyo, Japan.
Clin Neuroradiol. 2022 Mar;32(1):153-162. doi: 10.1007/s00062-021-01085-3. Epub 2021 Sep 8.
To investigate the effect of alteplase, either combined with stent-retriever thrombectomy or a direct aspiration first pass technique (ADAPT), in patients with large-vessel occlusion stroke.
This was a retrospective post hoc analysis of data from The Direct Mechanical Thrombectomy in Acute LVO Stroke (SKIP) study. Patients were divided into two groups according to the first-line thrombectomy technique: stent-retriever and ADAPT. Each group was further divided into two subgroups, namely MT and MT + alteplase. The procedural outcomes, such as first pass effect (FPE) ratio and number of passes, were evaluated. The clinical outcomes included mRS score at 3 months.
A total of 180 patients were included (116 in the stent-retriever group and 64 in the ADAPT group). No interaction was detected between the first-line technique and alteplase administration. In the stent-retriever group, after adjusting for factors associated with FPE, the adjusted odds ratio (95% confidence interval) of FPE of the MT + alteplase subgroup versus the MT subgroup was 3.57 (1.5-8.48) and in the ADAPT group it was 1.35 (0.37-4.91). With alteplase, the number of passes decreased with adjusted odds ratios of 0.59 (0.37-0.93) in the stent-retriever group but not in the ADAPT group. In both first-line technique groups, clinical outcomes did not differ between subgroups.
In the SKIP study, alteplase administration was associated with increased FPE when combined with stent-retriever thrombectomy, but not with ADAPT. We found no differences in the clinical outcomes.
研究阿替普酶联合支架取栓术或直接抽吸首过技术(ADAPT)对大血管闭塞性脑卒中患者的影响。
这是一项对急性大血管闭塞性卒中直接机械取栓(SKIP)研究数据的回顾性事后分析。根据一线取栓技术将患者分为支架取栓组和 ADAPT 组。每组进一步分为支架取栓术和支架取栓术联合阿替普酶两组。评估了手术结果,如首过效应(FPE)率和通过次数。临床结局包括 3 个月时 mRS 评分。
共纳入 180 例患者(支架取栓组 116 例,ADAPT 组 64 例)。未发现一线技术与阿替普酶给药之间存在交互作用。在支架取栓组中,在调整与 FPE 相关的因素后,支架取栓术联合阿替普酶组与单纯支架取栓组的 FPE 调整比值比(95%置信区间)为 3.57(1.5-8.48),而在 ADAPT 组为 1.35(0.37-4.91)。阿替普酶组中,通过次数减少,调整比值比为 0.59(0.37-0.93),而在 ADAPT 组中无此变化。在两组一线技术组中,亚组间临床结局无差异。
在 SKIP 研究中,阿替普酶联合支架取栓术可增加 FPE,但与 ADAPT 联合使用则不然。我们发现临床结局无差异。